Cannabis Terpenes Show Promise for Fibromyalgia and Post-Surgical Pain Relief Without Psychoactive Effects
Key Insights
University of Arizona researchers found four cannabis terpenes—geraniol, linalool (search), beta-caryophyllene, and alpha-humulene (search)—produced significant pain relief in preclinical mouse models of fibromyalgia (search) and post-operative pain.
Geraniol demonstrated the strongest analgesic effects, and all four compounds acted through the adenosine A2a receptor (search) without producing THC-like psychoactive effects.
Fibromyalgia (search) affects up to 5% of the global population and approximately 4 million U.S. adults, while roughly 310 million major surgeries are performed worldwide annually, underscoring the need for non-opioid alternatives.
A new preclinical study from the University of Arizona Health Sciences has demonstrated that terpenes—aromatic compounds found in Cannabis sativa—can produce substantial pain relief in mouse models of fibromyalgia (search) and post-operative pain, without the psychoactive effects associated with THC. The findings, led by John Streicher, PhD, professor in the Department of Pharmacology at the U of A College of Medicine – Tucson and member of the Comprehensive Center for Pain & Addiction, represent the first investigation of terpenes in these specific pain models.
Four Terpenes Tested, Geraniol Leads the Pack
The research team examined four terpenes commonly found in Cannabis sativa: geraniol, linalool (search), beta-caryophyllene, and alpha-humulene (search). All four compounds produced meaningful pain-relieving effects in the preclinical models, with geraniol delivering the strongest response, followed by linalool, beta-caryophyllene, and alpha-humulene.
"Our research is showing that terpenes are not a good option for reducing acute pain resulting from an injury, such as stubbing your toe or touching a hot stove; however, we are seeing significant reductions in pain when terpenes are used for chronic or pathological pain," said Streicher. "This study was the first to investigate the impact of terpenes in preclinical models of fibromyalgia (search) and post-operative pain and expand the scope of potential pain-relieving treatments using terpenes."
A New Avenue for Fibromyalgia (search) Treatment
Fibromyalgia (search) remains one of the most challenging chronic pain conditions to manage. The disorder, which affects muscles and soft tissues throughout the body, is estimated to impact up to 5% of the global population, according to research published in Healthcare (Basel) in 2023. In the United States alone, approximately 4 million adults live with fibromyalgia, according to the U.S. Department of Health and Human Services' Office on Women's Health, with women disproportionately affected.
"With fibromyalgia (search), there isn't much understanding of what the pain state is, and there are not a lot of great options for treating it," Streicher noted. "Our findings show that terpenes may be a viable treatment option for fibromyalgia pain, which could potentially have a large impact and make a difference for an under-treated population."
Post-Surgical Pain: A Middle Ground with Unmet Needs
The study also explored terpenes' potential in post-operative pain, which occupies a unique position between acute and chronic pain. Although typically temporary, surgery triggers biological changes—including inflammation and heightened sensitivity within the body's pain pathways—that can intensify discomfort.
"Opioids do a good job controlling post-surgical pain, but they can cause constipation that can increase the chances of post-surgical complications such as adhesions," Streicher explained. "We are always looking for better options, and this study suggests that terpenes could be a novel therapeutic for post-operative pain."
The scale of the need is substantial: roughly 310 million major surgical procedures are performed worldwide each year, according to research published in the International Journal of Surgery in 2020.
Mechanism Tied to Adenosine A2a Receptor (search)
The study builds on earlier work from Streicher's lab, which had previously found that terpenes could reduce pain in models of inflammation and chemotherapy-related nerve damage. The new findings indicate that the pain-relieving effects are linked to the adenosine A2a receptor (search)—the same receptor that caffeine targets and blocks—suggesting that terpenes may also possess sedative properties. The researchers note that this possibility warrants further investigation.
Nature as a Source of Drug Discovery
Todd Vanderah, PhD, director of the Comprehensive Center for Pain & Addiction at U of A Health Sciences and head of the Department of Pharmacology, emphasized the broader significance of the findings for natural product drug discovery.
"The research that is being done by Dr. Streicher's lab on terpenes and their potential to help those who suffer from chronic pain demonstrates the importance of basic research. There are hundreds of unique chemicals that plants make, including the Cannabis plant, that are undiscovered," Vanderah said.
He drew a parallel to another notable natural-product-derived medication: "Nature is incredible at making unique chemical structures, and many of these chemicals are unknowns when it comes to their abilities to aid in human health, diseases and disorders. A great current example is medication semaglutide, sold under the brand name Ozempic, which has a chemical structure that was isolated not from a plant, but from an animal that is prevalent in the Southwest, the Gila monster. These discoveries from natural products through research such as Dr. Streicher's can result in very useful medications."
The study's co-authors included Caleb Seekins, a former undergraduate biochemistry student now pursuing a medical degree at the College of Medicine – Tucson; Alyssa Welborn, who earned a Bachelor of Science in Pharmaceutical Sciences in 2024; and Abigail Schwarz, who completed her doctorate in Streicher's lab in 2024. Funding was provided by the National Institutes of Health under award number R01AT011517.